Biocon Limited — JV/Acquisition, 06-12-2025: Acquisition

Biocon Ltd. announced a strategic move to fully integrate its material subsidiary, Biocon Biologics (BBL), by acquiring minority stakes from Mylan, Serum, Tata Capital, and Activ Pine. This aims to simplify the corporate structure, unify capital allocation, and unlock operational synergies for enhanced scale and market reach. The deal involves issuing Biocon shares worth ₹6,950 Cr and a cash payment of USD 400 million. Biocon will also raise up to ₹4,500 Cr via QIP/rights issue and ₹1,800 Cr through Commercial Papers for funding. This integration strengthens Biocon's position in the biosimilars market.